Home Antibody All anti-BRCA1 antibodies
Anti-BRCA1 TRUEMAB Antibody Clone 2A5
TrueMAB Antibodies - Made against Authentic Protein Antigens
Also for BRCA1 (NM_007296)
|Human recombinant protein fragment corresponding to amino acids 1151-1473 of human BRCA1 (NP_009225) produced in E.coli.|
|| WB 1:2000,
|PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.|
|Purified from mouse ascites fluids by affinity chromatography
|Homo sapiens breast cancer 1, early onset (BRCA1), transcript variant BRCA1a'|
|BRCAI; BRCC1; BROVCA1; IRIS; PSCP; RNF53; BRCC1; IRIS; PSCP; RNF53; BRCA1/BRCA2-containing complex, subunit 1; breast and ovarian cancer susceptibility protein 1; breast cancer 1, early onset|
|This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009]. |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY BRCA1 (RC218344, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-BRCA1.